ProCE Banner Activity

Mitigation and Management of Ocular Toxicity in Patients Receiving Antibody–Drug Conjugates

Multimedia
Watch this on-demand Webcast capturing expert presentations focused on the mechanism of corneal toxicity in patients with cancer receiving antibody–drug conjugates and strategies for optimal monitoring and management.

Released: January 20, 2021

Expiration: January 19, 2022

Share

Faculty

Asim V. Farooq

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Anthony J. Perissinotti

Anthony J. Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Learning Objectives

  • Apply the available data and expert recommendations to optimally monitor for ocular toxicity in patients with cancer who are receiving antibody–drug conjugates
  • Plan appropriate therapeutic interventions with treating hematologists and oncologists in patients experiencing ocular toxicities from antibody–drug conjugate therapy to maximize clinical outcomes from anticancer therapy and mitigate worsening keratopathy

Program Director Disclosure

Program Director

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Asim V. Farooq, MD, has disclosed that he has received consulting fees from GlaxoSmithKline.

Faculty Disclosure

Primary Author

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Sanofi, and Takeda; has received funds for research support from Bristol-Myers Squibb, Janssen, and Takeda; and has ownership interest in TG Therapeutics.

Anthony J. Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan

Anthony Perissinotti, PharmD, BCOP, has disclosed that he has received consulting fees from Amgen, Astellas, Celgene/Juno, Coherus BioSciences, and Servier.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.